Background/Aims: Non-radical primary tumour resection (PTR) of asymptomatic metastatic colorectal cancer (mCRC) can prolong survival time of some patients. Patients with mutated RAS gene have worse survival outcome. This study aimed to investigate the impact of RAS gene mutations on the prognosis of asymptomatic unresectable mCRC patients who underwent PTR. Methods: A retrospective observational cohort study was deduced among mCRC patients who experienced PTR or had intact primary tumour (IPT). All of them had the primary tumour tissue genotyping tested for RAS (KRAS and NRAS) gene mutations. The tumour-related overall survival (OS) time and progression-free survival (PFS) time was estimated. From January 2011 to June 2014, 421 mCRC patients with asymptomatic, unresectable, metastatic disease were enrolled in this study. Among them, 282 patients underwent PTR and 139 patients had IPT. Results: The mutation rate of RAS was 53.8% (221/411). With a median followed-up time of 46.5 months, the overall survival time of mCRC patients harboring wtRAS or mtRAS was 28.0 versus 22.0 months (p = 0.043) in PTR group and was 21.6 versus 17. 
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Introduction
Colorectal cancer (CRC) is a common type of malignant tumour worldwide. Almost 20% -25% of patients with CRC have metastatic disease at the time of initial diagnosis and 75% -90% of them were unresectable [1] . The median survival time of metastatic colorectal cancer (mCRC) patients presenting with unresectable distant metastasis was about 5 months with best supportive care [2, 3] .
In general, the purpose of primary tumour resection (PTR) is to prevent or treat colon or rectal primary tumour related complications, such as intestinal obstruction, acute significant bleeding, perforation and systemic chemotherapy related complications brought from new molecular target therapy drugs (e.g. anti-angiogenesis monoclonal antibody) for colorectal cancer patients who had unresectable metastatic lesions [4] . But, considerable retrospective studies have suggested that CRC patients with asymptomatic primary tumour as well as synchronous unresectable metastases who underwent PTR had significantly longer survival time compared to those who only received palliative systemic chemotherapy [5] [6] [7] . A series of perspective clinical trials have been carried out to verify the survival superiority of PTR in this setting, such as CAIRO4 [NCT01606098], SYNCHRONOUS [ISRCTN30964555] and Korean trial [NCT01978249] [8] [9] [10] .
It is crucial that oncologists should make a decision for asymptomatic unresectable mCRC patients who are most likely to be benefited from the non-curative resection of primary tumour. Dorajoo SR et al. [11] reported that clinical features, such as advanced age, poorly differentiated tumour, metastasis to liver, lung and bone, carcinomatosis, hypoalbuminaemia and elevated carcinoembryonic antigen levels, could significantly shorten post-operative survival of PTR. DeMestier et al. [12] summarized that other clinicpathological characteristics, including WHO-PS score, primary tumour site, chemotherapy regimen, liver metastasis burden and extra-hepatic metastatic disease were also the independent prognostic factors. Turner N et al. [13] suggested that systemic inflammation was also a negative factor form CRC patient who experience PTR.
The genetic features classification is regarded as basis for personalized therapy in mCRC in recent years, yet only RAS (KRAS, NRAS) and BRAF mutation have so far been wildly accepted as the biomarkers tools in clinical practice to help doctors administrate right therapy for right patients at the right time. The utility of BRAF gene as a biomarker is limited because BRAF V600E mutation rate is about 5% to 9% among colorectal cancer [14] . The RAS mutations prevalence (exon 2 and non-exon 2 of KRAS and NRAS) ranges from 50% to 60% [15] and have been taken as a predictive marker of resistance to EGFR blockage target therapy in conventional practice use [16] . RAS mutations may also have negative impact on patients' prognosis in metastatic setting. Osumi H et al. [17] evaluate the relationship between RAS mutations and clinical survival outcomes after mastectomy in mCRC patients and demonstrated that mutant-type RAS (mtRAS) was associated with shorter overall survival time. Waring P et al. [18] suggested that KRAS mutations in mCRC predispose to aggressive biology and possibly selection for therapy resistant clones. Payandeh M et al. [19] reported that there was a significant difference of KRAS codons mutations for survival.
At the present time, there are no biomarkers so far that have been identified to be a favorable predictor of PTR clinical survival outcome. Whether RAS mutation is related to a worse survival even if mCRC patients presented asymptomatic disease and undergo PTR remains uncertain. Therefore, we designed this retrospective observational study, trying to examine the impact on clinical survival among the population of mCRC patients who experienced PTR and verify the prognostic value to determine the subpopulation who would be really benefited from the non-curative surgery procedure.
RAS mutations analysis
Tumour specimen was from formalin-fixed, paraffin-embedded resected primary tumour mass or biopsy tissue under endoscopy. DNA extracted by FFPE QIAGNE kit and RAS statues were analyzed by the amplification refractory mutation system (ARMS). KRAS mutations referred to exon 2 (codons 12, 13), exon 3 (codons 59, 176, 181), exon 4 (codons 146, 117). NRAS mutations referred to exon 2 (codons 12, 13), exon 3 (codons 59, 61), exon 4 (codons 146, 117).
Assessment measure of treatment outcomes
The patients were radiologically examined every six to eight weeks to assess treatment response according to clinical guidelines, such as the NCCN guideline, which recommend abdominopelvic computed tomography (CT) scans, liver magnetic resonance imagines (MRI), and chest X-rays. If chest X-rays indicated metastatic disease in the lungs, chest CT scans were performed to confirm the diagnosis. The assessments were performed immediately if clinical signs indicated disease progression. A complete CBC with differentials and chemistry profiles was performed prior to each cycle. Objective tumour responses were measured according to the RECIST 1.1 criterion, including complete response (CR), partial response (PR), stable disease (SD) and progressive disease (PD). During treatment, hematological toxicities and nonhematological toxicities were assessed according to the National Cancer Institute Common Toxicity Criteria (NCI-CTC) scale version 3.0 [20] . Progression free survival (PFS) time was calculated from the initial of the treatment until disease first progression and overall survival (OS) time was referred to time until the date of death or last follow-up.
Statistical analysis
The statistical analyses were conducted with software of SPSS (version 12.0). Clinical characteristics were examined using the Chi squared test or Fisher's exact probability test. Time-related parameters were evaluated using the Kaplan-Meier method and were compared by Log-rank test.
Results
The prevalence of RAS gene mutation From January 2011 to June 2014, a total of 1029 metastatic colorectal patients were first diagnosed and treated at the Department of Medical Oncology of Zhongshan Hospital affiliated to Fudan University. Finally, there were 421mCRC patients were enrolled in this study, with 282 cases underwent primary tumour resection and 139 cases had intact primary tumour. Four hundred and eleven cases successfully genotyped for RAS gene mutations. There were 176 cases and 45 cases detected mutated-type KRAS (42.8%) and NRAS (10.9%). In addition, there were 24 cases with wild-type RAS detected mutated-type BRAF of V600E (24/411, 5.8%). The date of PTR and IPT group was showed in Fig. 1 (Table 3) .
Tumour-related Survival analysis
With a median time of 46.5 (12-51) months, three hundred and ninety (390/411 ，94%) patients died of tumour. The progression free survival time and overall survival time of mCRC patients who underwent PTR or had IPT was 9.2 versus 7.7 months (p = 0.005) and 26.0 versus 15.5 months (p = 0.001) (Fig. 2) . The progression free survival time of mCRC patients who underwent PTR or had IPT with wtRAS or mtRAS were 10.8 versus 8.5 months (p = 0.059), 7.9 versus 6.8 months (p = 0.893) (Fig. 3) . The overall-survival time of mCRC patients who underwent PTR or had IPT with wtRAS or mtRAS were 28.0 versus 21.6 months (p = 0.024), 22.0 versus 17.8 months (p = 0.102) (Fig. 4) . Then, the progression free survival time of mCRC patients who harbored wtRAS or mtRAS experienced PTR or IPT were 10.8 versus 7.9 months (p = 0.032), 8.5 versus 6.8 months (p = 0.095) (Fig. 5) . The overall-survival time of mCRC patients who harbored wtRAS or mtRAS experienced PTR or IPT were 28.0 versus 22.0 months (p = 0.043), 21.6 versus 17.8 months (p = 0.071) (Fig. 6) , respectively. A statistical significance was proved by log-rank test. were independent prognostic factors in IPT population (Table  6 ).
Discussion
The result of this study suggested that asymptomatic unresectable mCRC patients with wtRAS gene who experienced primary tumour resection had a longer overall survival time and progression free survival time than those had mtRAS gene. Inversely, mCRC patients with mtRAS gene had a similar survival outcome, regardless of whether they underwent primary tumour resection or had intact tumour all the time.
Regardless of a retrospective observational cohort study with small sample, the results of this study suggested a significant difference and condition, which lacked reports. There were no significant differences in baseline characteristics between the PTR and IPT group, such as clinic pathological features of primary and metastastic lesions, chemo-or molecular therapy regimens and response to systemic treatments. The similar RAS mutation prevalence and survival outcomes were found by this research group according to the literature reported in metastatic setting.
A recent pooled analysis suggested that RAS mutation (including KRAS and NRAS) prevalence in mCRC patients was about 55.9%, with a distribution as: 42.6% KRAS exon 2, 3.8% KRAS exon 3, 6.2% KRAS exon 4, 2.9% NRAS exon 2, 4.2% NRAS exon 3, 0.3% NRAS exon 4 [21] . In our study, there were 221 cases detected of RAS mutation among 435 valid results (50.8%), followed by KRAS exon 2 (163, 37.5%), KRAS exon 3 (7, 1.6%), KRAS exon 4 (6, 1.4%), NRAS exon 2 (19, 4.3%), NRAS exon 3 (14, 3.2%) and NRAS exon 4 (12, 2.7%).
The presence of KRAS mutation indicated an increasing risk of recurrence and death in RASCAL I and RASCAL II study of patients with Duke's stage C disease [22, 23] . In fact, the prognostic impact of KRAS mutation on survival of colorectal cancer patients among advanced disease population was controversial, because many non-EGFR (Epidermal Growth Factor Receptor) containing regimen of systemic treatment failed in exhibiting a difference of outcome between wtKRAS and mtKRAS CRC in some studies [24] [25] [26] [27] . On the other hand, RAS mutation may present a negative factor for the surgery treatment of advanced patient [28, 29] . Kodaz et al. [30] reported that KRAS mutation had a worse prognostic impact on the metastatic CRC patients who underwent curative resection of liver metastasis. Vauthey et al. [31] found out that RAS mutations predicted early lung recurrence among those who had curative resection of colorectal liver metastases and suggested that surgical treatment contributed to prolongation of survival in the population of stage IV colorectal cancer patients and the outcome could be affected by the RAS mutation. In fact, RAS mutation arose early in the process of CRC by polyp-adenoma-neoplasia sequence. A more recent study deduced by Galanopoulos M and his colleagues and revealed that patients with CRC, polyps and healthy individuals could be discriminated by blood circulation free DNA when they underwent screening colonoscopy, because of the mutations in single nucleotide polymorphism (SNP) of KRAS gene [32] . Currently, preclinical studies have already demonstrated that mtRAS is the potential reason of EGFR target therapy resistance. Results from our study have also suggested that mCRC patients harboring mtRAS molecular characteristics may be a class of population who cannot benefit from active surgery treatment.
Some retrospective studies suggested a trend of survival advantage of PTR. Clancy C et al. [33] deduced a meta-analysis of 21 studies and revealed that PTR for mCRC patients was associated with a lower mortality risk (OR 0.28; 95 % CI 0.165-0.474; P < 0.001) and translated into a difference mean survival of 6.4 months in favor of resection (95 % CI 5.025- 7.858, P < 0.001). Ahmed S et al. [34] found that median survival was 15.2 months (range: 10-30.7 months) in the resection group and 11.4 months (range: 3-22 months) in the nonresection group among mCRC patients from 15 retrospective observational studies. Given that inevitable basic flaws lied in selection bias of these studies, such as good performance status, younger age, oligo metastasis and so on , which suggested that those who experienced PTR could be a better prognosis population among advanced mCRCs patients, the systemic therapy was taken as an canonical initial treatment for the advanced unresectable diseases by the major clinical guidelines from the National Comprehensive Cancer Network (NCCN), the European Society for Medical Oncology (ESMO) and the American Society for Medical Oncology (ASCRS). The non-radical surgery of the primary tumor was not recommended by current clinical guidelines, even if the patients had a good performance and presented no severe tumour related symptoms. Although we compared the prognosis survival of PRT to IPT (Fig. 2, Fig. 3 , Table 4 ), this was not the main research conclusion in our study. In fact, it is difficult to ethically initiate a prospective randomized controlled clinical trial for asymptomatic unresectable mCRC patients to verify palliative resection or palliative systemic chemotherapy which is an optimal treatment choice for them.
However, Chinese colorectal cancer patients who are initially diagnosed as metastatic diseases are more willing to have a non-radical resection rather than receive palliative systemic chemotherapy until disease progression, which gave us a favorable opportunity to launch this retrospective observational cohort study [35] . In our center, the decision of receiving PTR treatment was made according to patients' intention, surgeons' assessment of surgery treatment risk as well as some other patients' condition and clinical features, such as abdominal pain, bloating and other mild symptoms which suggested probable aggravation.
Although a Consensus Molecular Subtypes (CMS) Consortium analyzed CRC expression profiling data from multiple studies and classified CRC into four CMS groups with distinguishing features: CMS1 (microsatellite instability immune, 14%), hyper mutated, microsatellite unstable and strong immune activation; CMS2 (canonical, 37%), epithelial, marked WNT and MYC signaling activation; CMS3 (metabolic, 13%), epithelial and evident metabolic dysregulation; and CMS4 (mesenchymal, 23%), prominent transforming growth factor-β activation, stromal invasion and angiogenesis [36] , the attempts to find out molecular markers that can predict tumour disease outcomes regardless of treatment therapy (prognostic) or that give information about the effect from a specific treatment (predictive) have had limited advance in mCRC. Due to low mutation rate of BRAF about 5% to 13%, which appeared 5.9% (24/401) in this study, all RAS gene including KRAS and NRAS examination represents a more valuable tool for predictive and prognostic biomarker than BRAF. Gene mutations provide information beyond that provided by the clinic-pathologic characteristics, such as primary tumour size, site (right colon or left colon), multi-/oligometastasis, CEA and CA-199 level, related to the primary tumour as well as metastases, for example, tumor site was not a significant prognostic factors by a multivariate analysis between PTR and IPT.
In addition, the case enrolled in our study was treated much earlier. Patients with asymptomatic unresectable metastases of CRC mainly received systemic chemotherapy and primary tumor resection in our center at that time. Local treatment of liver metastases was not fully in accordance with the current MDT (multidisciplinary team treatment) strategy. Loco regional therapies of the liver metastasis were not commonly used in this study population. Patients with resectable, potentially resectable, potentially topical treatable metastasis were excluded in this study. However, we believed that these did not affect the basic observation of the relationship between RAS gene and survival outcomes in this study. Patients who received PRT were likely to have a better prognosis inherently. It was the purpose of this retrospective cohort study that if they harbored wtRAS gene, they could further benefit from the PTR.
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